With Another Financing of Nearly 100 Million Yuan, Cascade Accelerated Its Competition for Nuclear Receptor and GPCR Innovative Drug Research and Development

In January 2022, Cascade announced the completion of nearly 100 million yuan of pre-A+round financing to accelerate the follow-up research and development of several core products of the company. This round of financing is led by the funds of the new investor West Lake Innovation (Hangzhou) Equity Investment Co., Ltd., and the old shareholders such as Gaorong Capital, Fuhui Venture Capital, and Jindi Capital continue to invest together.